<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "https://pharmacia.pensoft.net/nlm/tax-treatment-NS0.dtd">
<article xmlns:tp="http://www.plazi.org/taxpub" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">89</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:CCBBD2E1-BDAF-5702-AE4B-0E4910A4C7D6</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Pharmacia</journal-title>
        <abbrev-journal-title xml:lang="en">PHAR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0428-0296</issn>
      <issn pub-type="epub">2603-557X</issn>
      <publisher>
        <publisher-name>Bulgarian Pharmaceutical Scientific Society</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3897/pharmacia.73.e190550</article-id>
      <article-id pub-id-type="publisher-id">190550</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Pharmacology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Real-world effectiveness of Ruxolitinib: analysis and comparison with COMFORT-II</article-title>
      </title-group>
      <contrib-group content-type="authors">
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Rangelov</surname>
            <given-names>Antoan</given-names>
          </name>
          <email xlink:type="simple">antoan.rangelov@gmail.com</email>
          <uri content-type="orcid">https://orcid.org/0000-0002-0163-6479</uri>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Ivanova</surname>
            <given-names>Boryana</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0003-2466-9254</uri>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Manova</surname>
            <given-names>Manoela</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0002-8749-7974</uri>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Kondeva</surname>
            <given-names>Galya</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Savova</surname>
            <given-names>Alexandra</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0003-4579-5524</uri>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line content-type="verbatim">Sofia University “Saint Kliment Ohridski”, Sofia, Bulgaria</addr-line>
        <institution>Sofia University “Saint Kliment Ohridski”</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
        <uri content-type="ror">https://ror.org/02jv3k292</uri>
      </aff>
      <aff id="A2">
        <label>2</label>
        <addr-line content-type="verbatim">National Council on Prices and Reimbursement of Medicinal Products, Sofia, Bulgaria</addr-line>
        <institution>National Council on Prices and Reimbursement of Medicinal Products</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
</aff>
      <aff id="A3">
        <label>3</label>
        <addr-line content-type="verbatim">Medical University – Sofia, Sofia, Bulgaria</addr-line>
        <institution>Medical University – Sofia</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
        <uri content-type="ror">https://ror.org/01n9zy652</uri>
      </aff>
      <aff id="A4">
        <label>4</label>
        <addr-line content-type="verbatim">National Specialized Hospital for Active Therapy of Hematological Diseases, Sofia, Bulgaria</addr-line>
        <institution>National Specialized Hospital for Active Therapy of Hematological Diseases</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
        <uri content-type="ror">https://ror.org/030d7rf51</uri>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p>Corresponding author: Antoan Rangelov (<email xlink:type="simple">antoan.rangelov@gmail.com</email>)</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>07</day>
        <month>04</month>
        <year>2026</year>
      </pub-date>
      <volume>73</volume>
      <fpage>1</fpage>
      <lpage>7</lpage>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/5B971475-40B2-5278-A6EC-DD9301B7486E">5B971475-40B2-5278-A6EC-DD9301B7486E</uri>
      <history>
        <date date-type="received">
          <day>04</day>
          <month>03</month>
          <year>2026</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>03</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Antoan Rangelov, Boryana Ivanova, Manoela Manova, Galya Kondeva, Alexandra Savova</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>Abstract</label>
        <p>The analysis included 466 patients with myelofibrosis on treatment with ruxolitinib. The <abbrev xlink:title="progression free survival">PFS</abbrev> at 12<sup>th</sup>, 20<sup>th</sup>, 30<sup>th</sup>, 40<sup>th</sup>, and 50<sup>th</sup> month was 88%, 83%, 75%, 65%, and 61% respectively. Median for <abbrev xlink:title="progression free survival">PFS</abbrev> was reached at 73.5 months. <abbrev xlink:title="overall survival">OS</abbrev> median was reached at 48.2 months. <abbrev xlink:title="overall survival">OS</abbrev> at month 12<sup>th</sup>, 20<sup>th</sup>, 30<sup>th</sup>, and 40<sup>th</sup> month was 87%, 78%, 70%, and 56% respectively. Eligible patients for comparison with COMFORT-II trial after application of inclusion and exclusion criteria were 68, while the clinical trial included 146 patients. The estimated value for <abbrev xlink:title="progression free survival">PFS</abbrev> at 12<sup>th</sup> month was 84% and the median <abbrev xlink:title="progression free survival">PFS</abbrev> was reached at 35.3 months. The values for <abbrev xlink:title="overall survival">OS</abbrev> was estimated to be 74% at 12<sup>th</sup> month and the median of <abbrev xlink:title="overall survival">OS</abbrev> was reached at 30<sup>th</sup> month. The clinical benefit rate from real-world population was estimated at 98%, and objective response rate was estimated at 79.2%, based on 53 patients.</p>
      </abstract>
      <kwd-group>
        <label>Keywords</label>
        <kwd>Myelofibrosis</kwd>
        <kwd>ruxolitinib</kwd>
        <kwd>real-world data</kwd>
        <kwd>real-world evidence</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="Introduction" id="sec1">
      <title>Introduction</title>
      <p>Myelofibrosis (<abbrev xlink:title="Myelofibrosis">MF</abbrev>) is a myeloproliferative neoplasm (<abbrev xlink:title="myeloproliferative neoplasm">MPN</abbrev>) that can arise de novo (primary <abbrev xlink:title="Myelofibrosis">MF</abbrev>) or from other myeloproliferative neoplasms, specifically polycythemia vera (<abbrev xlink:title="polycythemia vera">PV</abbrev>) and essential thrombocythemia (<abbrev xlink:title="essential thrombocythemia">ET</abbrev>) (<xref ref-type="bibr" rid="B10">Harrison et al. 2020</xref>, <xref ref-type="bibr" rid="B3">Arber et al. 2022</xref>, <xref ref-type="bibr" rid="B12">Khoury et al. 2022</xref>). It is characterized by progressive bone marrow fibrosis, splenomegaly, and constitutional symptoms such as fatigue, weight loss, night sweats, fever and pruritus, which negatively impact the quality of life of patients (<xref ref-type="bibr" rid="B14">Mesa et al. 2016</xref>). In addition to the symptom burden <abbrev xlink:title="Myelofibrosis">MF</abbrev> is related to reduced overall survival (<abbrev xlink:title="overall survival">OS</abbrev>) in comparison to the general population and to patients with <abbrev xlink:title="essential thrombocythemia">ET</abbrev> and <abbrev xlink:title="polycythemia vera">PV</abbrev> (<xref ref-type="bibr" rid="B11">Hernández-Boluda et al. 2018</xref>, <xref ref-type="bibr" rid="B20">Tefferi 2021</xref>). Primary myelofibrosis is classified as a rare disease with reported prevalence of 1–9 per 100 000 (Orphanet n.d.).</p>
      <p>The disease pathophysiology is fundamentally driven by constitutive activation of the Janus kinase/signal transducer and activator of transcription (<abbrev xlink:title="Janus kinase/signal transducer and activator of transcription">JAK-STAT</abbrev>) signaling pathway (<xref ref-type="bibr" rid="B17">Schieber et al. 2019</xref>, <xref ref-type="bibr" rid="B8">Guijarro-Hernández and Vizmanos 2021</xref>). Ruxolitinib is an oral JAK1 and JAK2 inhibitor that was approved in 2011 by US Food and Drug Administration (<abbrev xlink:title="US Food and Drug Administration">FDA</abbrev>) and in 2012 by European Medicines Agency (<abbrev xlink:title="European Medicines Agency">EMA</abbrev>) for the treatment of patients with primary myelofibrosis, post polycythaemia vera myelofibrosis (PPV-<abbrev xlink:title="Myelofibrosis">MF</abbrev>) or post essential thrombocythaemia myelofibrosis (Post-<abbrev xlink:title="essential thrombocythemia">ET</abbrev><abbrev xlink:title="Myelofibrosis">MF</abbrev>) (<xref ref-type="bibr" rid="B6">EMA 2012</xref>). The pivotal Phase III COMFORT-I and COMFORT-II trials established ruxolitinib as the gold standard of care, demonstrating superior efficacy over both placebo and best available therapy (<abbrev xlink:title="best available therapy">BAT</abbrev>) in achieving a ≥ 35% reduction in spleen volume (<abbrev xlink:title="35% reduction in spleen volume">SVR35</abbrev>) and significant improvements in total symptom scores (<abbrev xlink:title="total symptom scores">TSS</abbrev>) (<xref ref-type="bibr" rid="B9">Harrison et al. 2012</xref>, <xref ref-type="bibr" rid="B22">Verstovsek et al. 2012</xref>). Long-term pooled analyses and real-world registries, such as the JUMP and ERNEST studies, have further validated these results, suggesting a durable clinical response and a significant survival advantage, with a reported 30% reduction in the risk of death compared to conventional therapies (<xref ref-type="bibr" rid="B21">Verstovsek et al. 2017</xref>, <xref ref-type="bibr" rid="B7">Guglielmelli et al. 2022</xref>).</p>
      <p>Despite the success of ruxolitinib in controlled clinical environments, its transition to routine practice reveals significant complexities. Clinical trials often employ strict eligibility criteria, typically excluding patients with advanced age, multiple comorbidities, or baseline cytopenias (platelets &lt; 100 × 10^9/L). In real-world populations, however, nearly one-third of patients present with moderate-to-severe thrombocytopenia, which often necessitates dose adjustment and potentially sub-optimal effect (<xref ref-type="bibr" rid="B19">Talpaz et al. 2018</xref>, <xref ref-type="bibr" rid="B5">Cervantes et al. 2021</xref>). Furthermore, while the therapeutic armamentarium has recently expanded to include second-generation JAK inhibitors such as fedratinib, momelotinib, and pacritinib (<abbrev xlink:title="European Medicines Agency">EMA</abbrev> application withdrawn in 2017), ruxolitinib continues to be the foundational therapy in global clinical practice. Given this longevity, there is an ongoing opportunity to refine its use through independent, regional real-world evidence (<abbrev xlink:title="real-world evidence">RWE</abbrev>). Such data are essential for characterizing treatment outcomes in heterogeneous patient populations who may present with clinical complexities not fully captured in the original landmark trials (<xref ref-type="bibr" rid="B4">Aruga et al. 2025</xref>).</p>
      <p>Ruxolitinib was included in the Positive drug list (<abbrev xlink:title="Positive drug list">PDL</abbrev>) in Bulgaria in 2014 for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis (<abbrev xlink:title="post polycythaemia vera myelofibrosis">PPV-MF</abbrev>) or post essential thrombocythaemia myelofibrosis. Inclusion in the <abbrev xlink:title="Positive drug list">PDL</abbrev> for medicinal products deemed as not cost-effective at the time of inclusion puts the product in the therapeutic effectiveness monitoring program, which includes collecting and analyzing real-world data.</p>
      <p>This study presents the results of the real-world data analysis of application of ruxolitinib for the treatment of adult patients with primary <abbrev xlink:title="Myelofibrosis">MF</abbrev>, PPV-<abbrev xlink:title="Myelofibrosis">MF</abbrev>, and post-<abbrev xlink:title="essential thrombocythemia">ET</abbrev><abbrev xlink:title="Myelofibrosis">MF</abbrev>. The results were compared to the COMFORT-II clinical trial results.</p>
    </sec>
    <sec sec-type="materials|methods" id="sec2">
      <title>Materials and methods</title>
      <sec sec-type="Study design" id="sec3">
        <title>Study design</title>
        <p>We performed a retrospective analysis of data from electronic health records for the period 2018–2024. Adult patients on treatment with ruxolitinib were followed up and their data collected and anonymized. All patients were diagnosed with myelofibrosis with ICD 10 classification code D47.1, and some of them were diagnosed also with <abbrev xlink:title="polycythemia vera">PV</abbrev> (ICD 10 classification code D45), essential thrombocythemia (ICD 10 classification code D47.3), and other specified neoplasms of uncertain or unknown behavior of lymphoid, haematopoietic and related tissue (ICD 10 classification code D47.7). The study analyzed the <abbrev xlink:title="overall survival">OS</abbrev>, <abbrev xlink:title="progression free survival">PFS</abbrev>, <abbrev xlink:title="clinical benefit rate">CBR</abbrev>, and <abbrev xlink:title="objective response rate">ORR</abbrev> and compared the results with COMFORT-II clinical trial results.</p>
      </sec>
      <sec sec-type="Data source" id="sec4">
        <title>Data source</title>
        <p>Data were obtained from healthcare establishments in Bulgaria, where the patients were treated and followed up. The data were extracted from structured and unstructured text through the implementation of <abbrev xlink:title="large language model">LLM</abbrev> algorithms. A sample of the extracted data was manually compared to the original medical documents and validated by two independent Data analysts. Data extraction was found to be at least 95% accurate for the analysed dataset. Data analysis was conducted via the Danny Platform (<ext-link xlink:href="https://sqilline.com/products/danny-platform/" ext-link-type="uri">https://sqilline.com/products/danny-platform/</ext-link>), an analytic platform that integrates large amounts of real-world data from EHRs using embedded machine learning and large language model (<abbrev xlink:title="large language model">LLM</abbrev>) algorithms. The results obtained were compared with the results of the COMFORT-II clinical trial, evaluating ruxolitinib versus the best available therapy for the treatment of primary myelofibrosis, myelofibrosis after polycythemia vera, or post-essential thrombocythemia myelofibrosis.</p>
      </sec>
      <sec sec-type="Comparison with clinical trial results" id="sec5">
        <title>Comparison with clinical trial results</title>
        <p>The endpoints reported were overall survival (<abbrev xlink:title="overall survival">OS</abbrev>), progression free survival (<abbrev xlink:title="progression free survival">PFS</abbrev>), clinical benefit rate (<abbrev xlink:title="clinical benefit rate">CBR</abbrev>), and objective response rate (<abbrev xlink:title="objective response rate">ORR</abbrev>). <abbrev xlink:title="progression free survival">PFS</abbrev> was defined as the time from initiation of ruxolitinib treatment to disease progression or death. <abbrev xlink:title="overall survival">OS</abbrev> was defined as the time from initiation of ruxolitinib treatment until death. <abbrev xlink:title="objective response rate">ORR</abbrev> was defined as the proportion of patients achieving partial or complete response to treatment over a specific period of time. <abbrev xlink:title="clinical benefit rate">CBR</abbrev> was defined as the proportion of patients achieving complete or partial response, or stable disease over a given time. The Kaplan–Meier method was used to estimate <abbrev xlink:title="progression free survival">PFS</abbrev> and <abbrev xlink:title="overall survival">OS</abbrev> from ruxolitinib initiation. The 95% confidence intervals for <abbrev xlink:title="objective response rate">ORR</abbrev> and <abbrev xlink:title="clinical benefit rate">CBR</abbrev> were calculated as per the Wilson score method for binomial variables.</p>
        <p>For the purpose of aligning characteristics, an Iterative Proportional Fitting (<abbrev xlink:title="Iterative Proportional Fitting">IPF</abbrev>) algorithm was used to adjust real-world data to match the data from the clinical trial. In this way, the progression-free survival (<abbrev xlink:title="progression free survival">PFS</abbrev>) and overall survival (<abbrev xlink:title="overall survival">OS</abbrev>) curves may be more comparable to those from the study. Additional inclusion and exclusion criteria were used in order to ensure comparability and homogeneity between real-world population and COMFORT-II population. There criteria are summarized in Table <xref ref-type="table" rid="T1">1</xref>.</p>
        <table-wrap id="T1" position="float" orientation="portrait">
          <label>Table 1.</label>
          <caption>
            <p>Inclusion and exclusion criteria for comparison with COMFORT-II.</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <th rowspan="1" colspan="1">Inclusion Criteria for comparison</th>
                <th rowspan="1" colspan="1">Exclusion Criteria for comparison</th>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Diagnosis code ICD 10 D47.1</td>
                <td rowspan="1" colspan="1">Spleen &lt; 5 cm below costal margin</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Age ≥ 18 years</td>
                <td rowspan="1" colspan="1">Peripheral blasts ≥ 10%</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">ECOG performance status 0–3</td>
                <td rowspan="1" colspan="1">Platelet count &lt; 100 × 10<sup>9</sup>/L</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">IPSS risk score: Intermediate-2 or High</td>
                <td rowspan="1" colspan="1">Absolute neutrophil count ≤ 1 × 10<sup>9</sup>/L</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
    </sec>
    <sec sec-type="Results" id="sec6">
      <title>Results</title>
      <p>The analysis includes patients (n = 466) diagnosed with myelofibrosis with ICD 10 code D47.1 receiving ruxolitinib. Nine patients were diagnosed with polycythemia vera, 82 with essential thrombocythemia, and 5 were diagnosed with ICD 10 code D47.7 - other specified neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue before or after being diagnosed with myelofibrosis (Table <xref ref-type="table" rid="T2">2</xref>).</p>
      <table-wrap id="T2" position="float" orientation="portrait">
        <label>Table 2.</label>
        <caption>
          <p>Demographics and clinical characteristics.</p>
        </caption>
        <table>
          <tbody>
            <tr>
              <th rowspan="1" colspan="1">Disease</th>
              <th rowspan="1" colspan="1">ICD-10 code</th>
              <th rowspan="1" colspan="1">n</th>
              <th rowspan="1" colspan="1">%</th>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="polycythemia vera">PV</abbrev>
              </td>
              <td rowspan="1" colspan="1">D45</td>
              <td rowspan="1" colspan="1">9</td>
              <td rowspan="1" colspan="1">2%</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="essential thrombocythemia">ET</abbrev>
              </td>
              <td rowspan="1" colspan="1">D47.3</td>
              <td rowspan="1" colspan="1">82</td>
              <td rowspan="1" colspan="1">18%</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Other</td>
              <td rowspan="1" colspan="1">D47.7</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">1%</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CMD</td>
              <td rowspan="1" colspan="1">D47.1</td>
              <td rowspan="1" colspan="1">466</td>
              <td rowspan="1" colspan="1">100%</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Sex</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">n</td>
              <td rowspan="1" colspan="1">%</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Female</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">220</td>
              <td rowspan="1" colspan="1">47%</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Male</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">246</td>
              <td rowspan="1" colspan="1">53%</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Age</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Value</td>
              <td rowspan="1" colspan="1">± SD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Average</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">68.9</td>
              <td rowspan="1" colspan="1">± 10.1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Median</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">71</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ECOG score</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Value</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">23</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">1</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">196</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">98</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">3</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">21</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">3</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">N/A</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">125</td>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The <abbrev xlink:title="progression free survival">PFS</abbrev> at 12<sup>th</sup>, 20<sup>th</sup>, 30<sup>th</sup>, 40<sup>th</sup>, and 50<sup>th</sup> month was 88%, 83%, 75%, 65%, and 61% respectively. Median was reached at 73.5 months. (Fig. <xref ref-type="fig" rid="F1">1</xref>)</p>
      <fig id="F1">
        <object-id content-type="doi">10.3897/pharmacia.73.e190550.figure1</object-id>
        <object-id content-type="arpha">B00ECBEA-B07B-5504-8389-A4F4DD4E6262</object-id>
        <label>Figure 1.</label>
        <caption>
          <p>Progression-free survival in all patients on ruxolitinib.</p>
        </caption>
        <graphic xlink:href="pharmacia-73-e190550-g001.jpg" id="oo_1586561.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1586561</uri>
        </graphic>
      </fig>
      <p>The results for <abbrev xlink:title="overall survival">OS</abbrev> showed that median was reached at 48.2 months. <abbrev xlink:title="overall survival">OS</abbrev> at 12<sup>th</sup>, 20<sup>th</sup>, 30<sup>th</sup>, and 40<sup>th</sup> month was 87%, 78%, 70%, and 56% respectively. (Fig. <xref ref-type="fig" rid="F2">2</xref>)</p>
      <fig id="F2">
        <object-id content-type="doi">10.3897/pharmacia.73.e190550.figure2</object-id>
        <object-id content-type="arpha">4470624E-609F-5646-A829-21ECE3E667D3</object-id>
        <label>Figure 2.</label>
        <caption>
          <p>Overall survival in all patients on ruxolitinib.</p>
        </caption>
        <graphic xlink:href="pharmacia-73-e190550-g002.jpg" id="oo_1586562.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1586562</uri>
        </graphic>
      </fig>
      <p>Based on 363 patients the clinical benefit rate is estimated at 96%. The data needed for calculation was not available for all patients.</p>
      <sec sec-type="Comparison with COMFORT-II" id="sec7">
        <title>Comparison with COMFORT-II</title>
        <p>Eligible patients for comparison with COMFORT-II trial after application of inclusion and exclusion criteria were 68, while the clinical trial included 146 patients. That allows for statistically significant results up to the 12<sup>th</sup> month time point. Not all of the clinical trial criteria were applied when selecting eligible patients from the real-world population, as the necessary data were not available for every patient and doing so would have resulted in too small a sample size for meaningful comparison.</p>
      </sec>
      <sec sec-type="Progression-free survival (PFS)" id="sec8">
        <title>Progression-free survival (PFS)</title>
        <p>The estimated value for <abbrev xlink:title="progression free survival">PFS</abbrev> at 6<sup>th</sup> month and 12<sup>th</sup> month was 93% and 84% respectively with the median <abbrev xlink:title="progression free survival">PFS</abbrev> reached at 35.3 months. Data for <abbrev xlink:title="progression free survival">PFS</abbrev> from COMFORT-II was not reported (Fig. <xref ref-type="fig" rid="F3">3</xref>).</p>
        <fig id="F3">
          <object-id content-type="doi">10.3897/pharmacia.73.e190550.figure3</object-id>
          <object-id content-type="arpha">CB199BC9-79D8-5774-AF07-F7EA17B8EC0E</object-id>
          <label>Figure 3.</label>
          <caption>
            <p>Progression-free survival in patients after <abbrev xlink:title="Iterative Proportional Fitting">IPF</abbrev>.</p>
          </caption>
          <graphic xlink:href="pharmacia-73-e190550-g003.jpg" id="oo_1586563.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/1586563</uri>
          </graphic>
        </fig>
      </sec>
      <sec sec-type="Overall survival (OS)" id="sec9">
        <title>Overall survival (OS)</title>
        <p>The values for <abbrev xlink:title="overall survival">OS</abbrev> for the real-world population was estimated to be 90% at 6<sup>th</sup> month, 74% at 12<sup>th</sup> month, and 59% at 18<sup>th</sup> month, while COMFORT-II reports 97%, 95%, and 88% for the same time points respectively. The median of <abbrev xlink:title="overall survival">OS</abbrev> in real-world population was reached at 30<sup>th</sup> month, while it was not reached in COMFORT-II trial (Fig. <xref ref-type="fig" rid="F4">4</xref>).</p>
        <fig id="F4">
          <object-id content-type="doi">10.3897/pharmacia.73.e190550.figure4</object-id>
          <object-id content-type="arpha">0F9CD6F9-1D25-5055-9B5C-D2F2AFF229AB</object-id>
          <label>Figure 4.</label>
          <caption>
            <p>Overall survival in patients after <abbrev xlink:title="Iterative Proportional Fitting">IPF</abbrev>.</p>
          </caption>
          <graphic xlink:href="pharmacia-73-e190550-g004.jpg" id="oo_1586564.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/1586564</uri>
          </graphic>
        </fig>
      </sec>
      <sec sec-type="Clinical benefit rate (CBR) and objective response rate (ORR)" id="sec10">
        <title>Clinical benefit rate (CBR) and objective response rate (ORR)</title>
        <p>The clinical benefit rate from real-world population was estimated at 98%, and objective response rate was estimated at 79.2%, based on 53 patients. These parameters were not reported in COMFORT-II and thus comparison can not be made.</p>
      </sec>
    </sec>
    <sec sec-type="Discussion" id="sec11">
      <title>Discussion</title>
      <p>In this real-world data study a total of 466 patients were followed up and their data analyzed. The median for <abbrev xlink:title="progression free survival">PFS</abbrev> was reached at 73.5 months, however enough patients for statistical significance were available until 55<sup>th</sup> month. The estimated progression-free survival in our cohort closely corresponds to the reported <abbrev xlink:title="progression free survival">PFS</abbrev> data from JUMP – 83% (95% CI, 79–88%) at 20<sup>th</sup> month vs 81% (95% CI, 78–83%) at week 96 (<xref ref-type="bibr" rid="B2">Al-Ali et al. 2020</xref>). The median for <abbrev xlink:title="overall survival">OS</abbrev> was reached at 48.2 months. The results from COMFORT trials showed that ruxolitinib was associated with significant improvement of <abbrev xlink:title="overall survival">OS</abbrev> compared to placebo or best available treatment (<xref ref-type="bibr" rid="B21">Verstovsek et al. 2017</xref>). Overall survival in patients with <abbrev xlink:title="Myelofibrosis">MF</abbrev> who received ruxolitinib compared with control populations, was evaluated in few real-world studies. Analysis of data from ERNEST study revealed that <abbrev xlink:title="overall survival">OS</abbrev> was significantly longer in ruxolitinib treated patients with <abbrev xlink:title="Myelofibrosis">MF</abbrev> in comparison to patients receiving hydroxyurea (Median: 6.7 years vs 5.1 years; p = 0.001) (<xref ref-type="bibr" rid="B7">Guglielmelli et al. 2022</xref>). А мulticenter, retrospective chart review, including 469 patients from six countries reported median survival from ruxolitinib initiation was 44.4 months (95% CI, 38.8–50.2 months) (<xref ref-type="bibr" rid="B16">Passamonti et al. 2022</xref>). (<xref ref-type="bibr" rid="B18">Stoeva et al. 2023</xref>) reported significant improvement in overall survival in Bulgarian patients population treated for <abbrev xlink:title="Myelofibrosis">MF</abbrev> with ruxolitinib compared with <abbrev xlink:title="best available therapy">BAT</abbrev>, estimating that 75% of patients on ruxolitinib would live for at least 80 months. Although real-world studies are associated with inherent limitations including limited data, limited number of patients, and risk of bias, and results vary, the findings are consistent and in agreement with prolonged <abbrev xlink:title="overall survival">OS</abbrev> in ruxolitinib treated patients in COMFORT trials.</p>
      <p>The <abbrev xlink:title="Iterative Proportional Fitting">IPF</abbrev> algorithm was applied to allow more precise comparison between our data and COMFORT-II data. This resulted in lower number of patients eligible for inclusion in the analysis compared to the entire population, 68 out of the 466. An additional limitation is that complete data were not available for every patient, owing to the nature of the data source, which consists of documents containing free-text entries and non-mandatory fields. There are differences in the criteria used to select patients from clinical practice compared to the criteria used in the clinical trial. Only a subset of the inclusion criteria was implemented in real-world practice to enable the inclusion of a larger study population. The number of patients in the clinical trial (146) is significantly higher than the number of patients in real-world practice (68). Consequently, the real-world data is sufficient for statistically significant conclusions only up to approximately the 12<sup>th</sup> month. The clinical trial does not present data for <abbrev xlink:title="progression free survival">PFS</abbrev> (Progression-Free Survival). The overall survival values in real-world practice compared to the clinical trial were as follows: 90% vs. 97% at 6<sup>th</sup> month, 74% vs. 95% at 12<sup>th</sup> month, and 59% vs. 88% at 18<sup>th</sup> month. The median <abbrev xlink:title="overall survival">OS</abbrev> in real-world practice was reached at 30<sup>th</sup> month, whereas in the clinical trial, it was not reached. The <abbrev xlink:title="clinical benefit rate">CBR</abbrev> (Clinical Benefit Rate) for ruxolitinib in clinical practice was 98% (52 out of 53 patients). The <abbrev xlink:title="objective response rate">ORR</abbrev> (Overall Response Rate) was 79.2% (42 out of 56 patients). There is no available data from the clinical trial to perform a direct comparison for these metrics. These results are consistent with the results from COMFORT-II and other real-world studies (<xref ref-type="bibr" rid="B9">Harrison et al. 2012</xref>, <xref ref-type="bibr" rid="B13">Meckstroth et al. 2021</xref>, <xref ref-type="bibr" rid="B1">Al-Ali et al. 2025</xref>).</p>
    </sec>
    <sec sec-type="Conclusions" id="sec12">
      <title>Conclusions</title>
      <p>Despite their limitations, real-world studies in <abbrev xlink:title="Myelofibrosis">MF</abbrev> are essential for the better understanding of the disease, treatment effectiveness and safety. Ruxolitinib remains the standard of care first line treatment for <abbrev xlink:title="Myelofibrosis">MF</abbrev>. Our findings affirm that ruxolitinib is a valuable treatment option for patients with <abbrev xlink:title="Myelofibrosis">MF</abbrev> and are consistent with other real-world studies and COMFORT-II clinical trial results.</p>
    </sec>
  </body>
  <back>
    <sec sec-type="Additional information" id="sec13">
      <title>Additional information</title>
      <p>
        <bold>Conflict of interest</bold>
      </p>
      <p>The authors have declared that no competing interests exist.</p>
      <p>
        <bold>Ethical statements</bold>
      </p>
      <p>The authors declared that no clinical trials were conducted in the present study.</p>
      <p>The authors declared that no experiments on humans or human tissues were performed for the present study.</p>
      <p>The authors declared that no informed consent was obtained from the humans, donors or donors’ representatives participating in the study.</p>
      <p>The authors declared that no experiments on animals were performed for the present study.</p>
      <p>The authors declared that no commercially available immortalised human and animal cell lines were used in the present study.</p>
      <p>This study was based on secondary usage of anonymized data. Ethics committee approval or patient-informed consent were not required for this type of research as per local Bulgarian regulations.</p>
      <p>
        <bold>Use of AI</bold>
      </p>
      <p>No use of AI was reported.</p>
      <p>
        <bold>Funding</bold>
      </p>
      <p>This study is financed by the European Union-NextGenerationEU through the National Recovery and Resilience Plan of the Republic of Bulgaria, project № BG-RRP-2.004-0004-C01.</p>
      <p>
        <bold>Author contributions</bold>
      </p>
      <p>All authors have contributed equally.</p>
      <p>
        <bold>Author ORCIDs</bold>
      </p>
      <p>Antoan Rangelov <ext-link xlink:href="https://orcid.org/0000-0002-0163-6479" ext-link-type="uri">https://orcid.org/0000-0002-0163-6479</ext-link></p>
      <p>Boryana Ivanova <ext-link xlink:href="https://orcid.org/0000-0003-2466-9254" ext-link-type="uri">https://orcid.org/0000-0003-2466-9254</ext-link></p>
      <p>Manoela Manova <ext-link xlink:href="https://orcid.org/0000-0002-8749-7974" ext-link-type="uri">https://orcid.org/0000-0002-8749-7974</ext-link></p>
      <p>Alexandra Savova <ext-link xlink:href="https://orcid.org/0000-0003-4579-5524" ext-link-type="uri">https://orcid.org/0000-0003-4579-5524</ext-link></p>
      <p>
        <bold>Data availability</bold>
      </p>
      <p>All of the data that support the findings of this study are available in the main text.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <mixed-citation>Al-Ali HK, Gerds AT, Grunwald MR, Yu J (2025) A Review of Real-World Experience With Ruxolitinib for Myelofibrosis. Clinical Lymphoma, Myeloma &amp; Leukemia 25: e262–e281. <ext-link xlink:href="10.1016/j.clml.2024.12.013" ext-link-type="doi">https://doi.org/10.1016/j.clml.2024.12.013</ext-link></mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, Le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM (2020) Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. British Journal of Haematology 189: 888–903. <ext-link xlink:href="10.1111/bjh.16462" ext-link-type="doi">https://doi.org/10.1111/bjh.16462</ext-link></mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gökbuget N, Gotlib J, Hellström-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian J-J, Larson RA, Le Beau MM, Loh ML-C, Löwenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui C-H, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien H-F, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H, Tefferi A (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140: 1200–1228. <ext-link xlink:href="10.1182/blood.2022015850" ext-link-type="doi">https://doi.org/10.1182/blood.2022015850</ext-link></mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>Aruga Y, Hongo W, Lu W (2025) Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study. Future Oncology 21: 3017–3026. <ext-link xlink:href="10.1080/14796694.2025.2550924" ext-link-type="doi">https://doi.org/10.1080/14796694.2025.2550924</ext-link></mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, Zachee P, Gisslinger H, Komatsu N, Foltz L, Mannelli F, Passamonti F, Gilotti G, Sadek I, Tiwari R, Zor E, Al-Ali HK (2021) Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia 35: 3455–3465. <ext-link xlink:href="10.1038/s41375-021-01261-x" ext-link-type="doi">https://doi.org/10.1038/s41375-021-01261-x</ext-link></mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>EMA (2012) Jakavi EPAR. <ext-link xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi#authorisation-details" ext-link-type="uri">https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi#authorisation-details</ext-link></mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Paoli C, Mannelli F, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larràn A, Andreasson B, Vannucchi AM, Barbui T (2022) Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Advances 6: 373–375. <ext-link xlink:href="10.1182/bloodadvances.2021006006" ext-link-type="doi">https://doi.org/10.1182/bloodadvances.2021006006</ext-link></mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>Guijarro-Hernández A, Vizmanos JL (2021) A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms. Cancers 13: 984. <ext-link xlink:href="10.3390/cancers13050984" ext-link-type="doi">https://doi.org/10.3390/cancers13050984</ext-link></mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine 366: 787–798. <ext-link xlink:href="10.1056/NEJMoa1110556" ext-link-type="doi">https://doi.org/10.1056/NEJMoa1110556</ext-link></mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>Harrison CN, Schaap N, Vannucchi AM, Kiladjian J-J, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA (2020) Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American Journal of Hematology 95: 594–603. <ext-link xlink:href="10.1002/ajh.25777" ext-link-type="doi">https://doi.org/10.1002/ajh.25777</ext-link></mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>Hernández-Boluda J, Correa J, Alvarez-Larrán A, Ferrer-Marín F, Raya J, Martínez-López J, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox M, Luño E, Kerguelen A, Cuevas B, Durán M, Ramírez M, Gómez-Casares M, Mata-Vázquez M, Regadera A, Pereira A, Cervantes F, the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN) (2018) Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. British Journal of Haematology 181: 397–400. <ext-link xlink:href="10.1111/bjh.14601" ext-link-type="doi">https://doi.org/10.1111/bjh.14601</ext-link></mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng W-J, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile J-F, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li X-Q, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A (2022) The 5<sup>th</sup> edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36: 1703–1719. <ext-link xlink:href="10.1038/s41375-022-01613-1" ext-link-type="doi">https://doi.org/10.1038/s41375-022-01613-1</ext-link></mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>Meckstroth S, Wang R, Ma X, Podoltsev N (2021) Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. Clinical Lymphoma, Myeloma &amp; Leukemia 21: e551–e558. <ext-link xlink:href="10.1016/j.clml.2021.01.025" ext-link-type="doi">https://doi.org/10.1016/j.clml.2021.01.025</ext-link></mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer 16: 167. <ext-link xlink:href="10.1186/s12885-016-2208-2" ext-link-type="doi">https://doi.org/10.1186/s12885-016-2208-2</ext-link></mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>Orphanet (n.d.) Knowledge on rare diseases and orphan drugs. <ext-link xlink:href="https://www.orpha.net/en/disease/detail/824?name=myelofibrosis&amp;mode=name" ext-link-type="uri">https://www.orpha.net/en/disease/detail/824?name=myelofibrosis&amp;mode=name</ext-link></mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>Passamonti F, Heidel FH, Parikh RC, Ajmera M, Tang D, Nadal JA, Davis KL, Abraham P (2022) Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review. Future Oncology 18: 2217–2231. <ext-link xlink:href="10.2217/fon-2021-1358" ext-link-type="doi">https://doi.org/10.2217/fon-2021-1358</ext-link></mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>Schieber M, Crispino JD, Stein B (2019) Myelofibrosis in 2019: moving beyond JAK2 inhibition. Blood Cancer Journal 9: 74. <ext-link xlink:href="10.1038/s41408-019-0236-2" ext-link-type="doi">https://doi.org/10.1038/s41408-019-0236-2</ext-link></mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>Stoeva V, Mihaylov G, Mitov K, Petrova G, Tachkov K (2023) Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study. Cancers 15: 5085. <ext-link xlink:href="10.3390/cancers15205085" ext-link-type="doi">https://doi.org/10.3390/cancers15205085</ext-link></mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>Talpaz M, Erickson-Viitanen S, Hou K, Hamburg S, Baer MR (2018) Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. Journal of Hematology &amp; Oncology 11: 101. <ext-link xlink:href="10.1186/s13045-018-0642-0" ext-link-type="doi">https://doi.org/10.1186/s13045-018-0642-0</ext-link></mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>Tefferi A (2021) Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. American Journal of Hematology 96: 145–162. <ext-link xlink:href="10.1002/ajh.26050" ext-link-type="doi">https://doi.org/10.1002/ajh.26050</ext-link></mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian J-J, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V (2017) Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology &amp; Oncology 10: 156. <ext-link xlink:href="10.1186/s13045-017-0527-7" ext-link-type="doi">https://doi.org/10.1186/s13045-017-0527-7</ext-link></mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine 366: 799–807. <ext-link xlink:href="10.1056/NEJMoa1110557" ext-link-type="doi">https://doi.org/10.1056/NEJMoa1110557</ext-link></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
